Epidémiologie, stratégies thérapeutiques et virologie cliniques dans l'infection à VIH
Accueil
FHDH
A propos de la base
Déjà 20 ans !
DOMEVIH
Principaux résultats
- RICE février 2013
- Publications
L'équipe
- Le GEC
- U1136 (ex-U943)
Collaborations
Etudes cliniques
ONCOVIH
Autres études
EPIDERMAS
FranceCoag
Doctorants - post-docs
EPICLIN 2010

Liste des publications à partir des données
de la base FHDH

2012 2011 2010
2005-2009 2000-2004 1992-1999

2005       31  
d'Arminio Monforte A, Sabin CA, Phillips A, Sterne J, May M, Justice A, Dabis F, Grabar S, Ledergerber B, Gill J, Reiss P, Egger M; The Antiretroviral Therapy Cohort Collaboration.
-->  The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy.
---->  Arch Intern Med. 2005 Feb 28;165(4):416-23.
        32  
Costagliola D, Potard V, Duvivier C, Pradier C, Dupont C, Salmon D, Duval X; French Hospital Database on HIV.
-->  Impact of newly available drugs on clinical progression in patients with virological failure after exposure to three classes of antiretrovirals.
---->  Antivir Ther. 2005;10(4):563-73.
        33  
Girardi E, Sabin CA, d'Arminio Monforte A, Hogg B, Phillips AN, Gill MJ, Dabis F, Reiss P, Kirk O, Bernasconi E, Grabar S, Justice A, Staszewski S, Fatkenheuer G, Sterne JA; Antiretroviral Therapy Cohort Collaboration.
-->  Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America.
---->  Clin Infect Dis. 2005 Dec 15;41(12):1772-82.
        34  
Grabar S, Le Moing V, Goujard C, Egger M, Leport C, Kazatchkine MD, Weiss L, Costagliola D.
-->  Response to highly active antiretroviral therapy at 6 months and long-term disease progression in HIV-1 infection.
---->  J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):284-92.
        35  
May M, Porter K, Sterne JAC, Royston P, Egger M, The Antiretroviral Therapy Cohort Collaboration and CASCADE (Concerted Action on SeroConversion to AIDS and Death in Europe).
-->  Prognostic model for HIV-1 disease progression in patients starting antiretroviral therapy was validated using independent data.
---->  Journal of Clinical Epidemiology 2005; 58: 1033-1041.
        36  
Sabin CA, Hogg B, Dabis F, Gill JM, Phillips AN, Reiss P, Fätkenheuer G, Grabar S, Lundgren J, Justice A, Ledergerber B, d’Arminio Monforte A, Staszewski S, Sterne JAC.
-->  AIDS events among individuals initiating HAART: do some patients experience a greater benefit from HAART than others?
---->  AIDS. 2005 Nov 18;19(17):1995-2000.
2006       37  
Abgrall S, Yeni PG, Bouchaud O, Costagliola D; the Clinical Epidemiology Group from the French Hospital Database on HIV.
-->  Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
---->  AIDS. 2006 Oct 24;20(16):2099-106.
        38  
Braitstein P, Brinkhof MWG, Dabis F, Schechter M, Boulle A, Miotti P, Wood R, Laurent C, Sprinz E, Seyler C, Bangsberg D, Balestre E, Sterne J, May M, Egger M; Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration and the ART Cohort Collaboration.
-->  Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries.
---->  Lancet 2006; 367: 817-824.
        39  
Fardet L, Mary-Krause M, Heard I, Partisani M, Costagliola D; for the French Hospital Database on HIV.
-->  Influence of gender and HIV transmission group on initial highly active antiretroviral therapy prescription and treatment response.
---->  HIV Med. 2006 Nov;7(8):520-529.
        40   
Fontaine C, Bonnard P, Mary-Krause M, Callard P, Pialoux G.
-->  Pulmonary pneumocystosis in a patient with greater than 500 CD4 cells/microl: a role for IL-2 therapy?
---->  AIDS. 2006 Aug 1;20(12):1680-1.
        41   
Grabar S, Abraham B, Mahamat A, Del Giudice P, Rosenthal E, Costagliola D.
-->  Differential impact of combination antiretroviral therapy in preventing Kaposi's sarcoma with and without visceral involvement.
---->  J Clin Oncol. 2006 Jul 20;24(21):3408-14.
        42   
Grabar S, Weiss L, Costagliola D.
-->  HIV infection in older patients in the HAART era.
---->  J Antimicrob Chemother. 2006 Jan;57(1):4-7.
        43  
Hernan MA, Lanoy E, Costagliola D, Robins JM.
-->  Comparison of dynamic treatment regimes via inverse probability weighting.
---->  Basic Clin Pharmacol Toxicol. 2006 Mar;98(3):237-42.
        44  
Hogg R, May M, Phillips A, Costagliola D, Sterne J, Sabin C, De Wolf F, Ledergerber B, D’Arminio Monforte A, Justice A, Gill J, Fusco G, Staszewski S, Rockstroh J, Chêne G, Egger M.
-->  Rates of disease progression according to initial highly active antiretroviral therapy regimen: a collaborative analysis of 12 prospective cohort studies.
---->  J Infect Dis. 2006 Sep 1;194(5):612-22.
        45  
Lanoy E, Mary-Krause M, Tattevin P, Dray-Spira R, Duvivier C, Fischer P, Obadia Y, Lert F, Costagliola D; Clinical Epidemiology Group of French Hospital Database on HIV Infection.
-->  Predictors identified for losses to follow-up among HIV-seropositive patients.
---->  J Clin Epidemiol. 2006 Aug;59(8):829-835. Epub 2006 May 30.
        46  
Lewden C, Jougla E, Alioum A, Pavillon G, Lievre L, Morlat P, Salmon D, May T, Chene G, Costagliola D; the Mortalite 2000 Study Group.
-->  Number of deaths among HIV-infected adults in France in 2000, three-source capture-recapture estimation.
---->  Epidemiol Infect. 2006 Dec;134(6):1345-52.
        47  
Lièvre L, Deveau C, Gerbe J, Enel P, Tran L, De Castro N, Costagliola D, Meyer L; Primo Study Group; Clinical Epidemieology Group.
-->  Yearly number of patients diagnosed with primary HIV-1 infection in France estimated by a capture-recapture approach.
---->  AIDS. 2006 Nov 28;20(18):2392-5.
        48  
Mary-Krause M, Billaud E, Poizot-Martin I, Simon A, Dhiver C, Dupont C, Salmon D, Roudiere L, Costagliola D; Clinical Epidemiology Group of the French Hospital Database.
-->  Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy.
---->  AIDS. 2006 Aug 1;20(12):1627-35.
        49  
May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC, Dabis F, Gill J, Lundgren J, Hogg RS, de Wolf F, Fatkenheuer G, Staszewski S, d'Arminio Monforte A, Egger M; Antiretroviral Therapy (ART) Cohort Collaboration.
-->  HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis.
---->  Lancet. 2006 Aug 5;368(9534):451-8.
2007       50   
Abgrall S, Yeni PG, Bouchaud O, Costagliola D; Clinical Epidemiology Group of the French Hospital Database on HIV.
-->  Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
---->  Clin Infect Dis. 2007 Jan 1;44(1):120-7.
        51  
Brinkhof MWG, Egger M, Boulle A, May M, Hosseinipour M, Sprinz E, Braitstein P, Dabis F, Reiss P, Bangsberg D, Rickenbach M, Meda JM, Myer L, Mocroft A, Nash D, Keiser O, Pascoe M, Van der Borght, Schechter M and the ART-LINC Collaboration of the International epidemiological Databases to Evaluate AIDS (IeDEA) and the ART Cohort Collaboration.
-->  Tuberculosis following initiation of antiretroviral therapy in low-income and high-income countries.
---->  Clin Infect Dis. 2007; 45: 1518-21.
        52  
Guiguet M, Furco A, Tattevin P, Costagliola D, Molina JM, and the French Hospital Database on HIV Clinical Epidemiology Group.
-->  HIV-associated Isospora belli infection: incidence and risk factors in the French Hospital Database on HIV.
---->  HIV Med. 2007; 8(2): 124–130.
        53   
Lanoy E, Mary-Krause M, Tattevin P, Perbost I, Poizot-Martin I, Dupont C, Costagliola D and ANRS CO04 French Hospital Database on HIV Clinical Epidemiological Group.
-->  Frequency, determinants and consequences of delayed access to care for HIV infection in France.
---->  Antivir Ther. 2007;12(1): 89-96.
        54  
May M, Sterne JAC, Sabin C, Costagliola D, Justice AC, Thiébaut R, Gill J, Phillips A, Reiss P, Hogg R, Ledergerber B, D’Arminio Monforte A, Schmeisser N, Staszewski S, Egger M.
-->  Prognosis of HIV-1 infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies.
---->  AIDS 2007; 21(9): 1185-1197.
        55  
Potard V, Rey D, Mokhtari S, Frixon-Marin V, Pradier C, Rozenbaum W, Brun-Vezinet F, Costagliola D; French Hospital Database on HIV, ANRS C04.
-->  First-line highly active antiretroviral regimens in 2001–2002 in the French Hospital Database on HIV: combination prescribed and biological outcomes.
---->  Antivir Ther. 2007;12(3):317-24.
        56  
Sterne J.A.C, May M, Sabin C,Phillips A,Costagliola D, Chêne, G, Justice A.C, de Wolf F, Hogg R, Battegay M, D’Arminio Monforte A, Fätkenheuer G, Staszewski S, Gill J, Egger M.
-->  Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients.
---->  J Acquir Immune Defic Syndr. 2007 Dec 15;46(5):607-15.
2008       57  
Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, Lambert PC, Porter K; CASCADE Collaboration.
-->  Changes in the risk of death after HIV seroconversion compared with mortality in the general population.
---->  JAMA. 2008; 300(1):51-9.
      58  
Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group.
-->  Response to combination antiretroviral therapy: variation by age.
---->  AIDS. 2008; 22(12): 1463-1473.
      59  
Grabar S, Lanoy E, Allavena C, Mary-Krause M, Bentata M, Fischer P, Mahamat A, Rabaud C, Costagliola D.
-->  Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy.
---->  HIV Med 2008; 9:246-256.
        60   
Guiguet M, Mary-Krause M, Ename B, Grabar S, Costagliola D.
-->  Influence of control selection in nested case-control studies: the example of exposure to antiretroviral treatment (ART) and the risk of myocardial infarction (MI) in the French Hospital Database on HIV (FHDH-ANRS CO4).
---->  Pharmacoepidemiol Drug Saf 2008 17(5): 468-474.
        61   
Guiguet M, Porter K, Phillips A, Costagliola D, Babiker A, on behalf of the CASCADE Collaboration.
-->  Clinical progression rates by CD4 cell category before and after the initiation of combination antiretroviral therapy (cART).
---->  The open AIDS journal 2008; 2: 3-9.
        62   
Harris RJ, Sterne JAC, Abgrall S, Dabis F, Reiss P, Saag M, Phillips AN, Chêne G, M Gill JM, Justice AC, Rockstroh J, Sabin CA, Mocroft A, Bucher HC, Hogg RS, D'Arminio Monforte A, May M, Egger M.
-->  Prognostic importance of anaemia in HIV-1 infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies in industrialized countries.
---->  Antivir Ther 2008;13(8): 959-967.
        63   
Hogg R, Lima V, Sterne J, Grabar S, Battegay M, Bonarek M, D'Arminio Monforte A, Esteve A, Gill J, Harris R, Justice A, Kitahata M, Lampe F, Mocroft A, Mugavero M, Staszewski S, Wasmuth JC, van Sighem A, Hayden A, Guest J, Egger M, May M.
-->  Life expectancy of persons on combination antiretroviral therapy (cART) in high-income countries.
---->  Lancet 2008;372:293-299.
        64  
Jarrin I, Geskus R, Bhaskaran K, Prins M, Perez-Hoyos S, Muga R, Hernández-Aguado I, Meyer L, Porter K, del Amo J; CASCADE Collaboration.
-->  Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women.
---->  Am J Epidemiol. 2008; 168(5):532-40.
        65  
Kousignian I, Abgrall S, Grabar S, Mahamat A, Teicher E, Rouveix E, Costagliola D; Clinical Epidemiology Group of the French Hospital Database on HIV.
-->  Maintaining antiretroviral therapy reduces the risk of AIDS-defining events in patients with uncontrolled viral replication and profound immunodeficiency.
---->  Clin Infect Dis. 2008 Jan 15;46(2):296-304.
        66  
Mouala C, Houzé S, Guiguet M, Abboud P, Pialoux G, Viget N, Costagliola C, and Matheron S.
-->  Imported malaria in HIV-infected patients enrolled in the ANRS CO4 FHDH study.
---->  J Acquir Immune Defic Syndr. 2008 Sep 1;49(1):55-60.
        67  
Mugavero MJ, May M, Harris R, Saag MS, Costagliola D, Egger M, Phillips A, Huldrych F. Günthard HF, Dabis F, Robert Hogg R, de Wolf F, Fatkenheuer G, Gill MJ, Justice A, D'Arminio Monforte A, Fiona Lampe F, Miró JM, Staszewski S, Sterne JAC.
-->  Does short-term virologic failure translate to clinical events in ARV-naïve patients initiating ART in clinical practice?
---->  AIDS 2008; 22(18):2481-92.
        68  
Pantazis N, Touloumi G, Vanhems P, Gill J, Bucher HC, Porter K; CASCADE Collaboration.
-->  The effect of antiretroviral treatment of different durations in primary HIV infection.
---->  AIDS 2008; 22(18): 2441-50
        69  
Piketty C, Selinger-Leneman H, Grabar S, Duvivier C, Bonmarchand M, Abramowitz L, Costagliola D, Mary-Krause M on behalf of the FHDH-ANRS CO4.
-->  Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy.
---->  AIDS 2008; 22:1203–1211
        70   
Selinger-Leneman H, Matheron S, Mahamat A, Moreau J, Costagliola D, Abgrall S; for the Clinical Epidemiology Group of the French Hospital Database on HIV (ANRS CO4).
-->  Dual nucleoside reverse transcriptase inhibitor therapy in the Combination antiretroviral therapy era and predictors of discontinuation or switch to combination antiretroviral therapy.
---->  J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):206-211
        71   
Touloumi G, Pantazis N, Stirnadel H, Walker SA, Boufassa F, Vanhems P, Porter K, on behalf of the CASCADE Collaboration.
-->  Rates and determinants of virologic and immunological response to HAART resumption after treatment interruption in HIV-1 clinical practice.
---->  J Acquir Immune Defic Syndr 2008; 49(5):492-498
2009       72   
Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Caro Murillo AM, Mocroft A, Bonnet F, Clifford G, Touloumi G, Miro JM, Chene G, Lundgren J, Egger M.
-->  Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy: European multi-cohort study.
---->  AIDS 2009; 23(15):2029-2037.
      73   
Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Caro Murillo AM, Mocroft A, Bonnet F, Clifford G, Karafoulidou A, Miro JM, Chene G, Lundgren J, Egger M.
-->  Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: European multi-cohort study.
---->  Antivir ther 2009; 14(8): 1065-74.
        74  
Chaix ML, Descamps D, Wirden M, Bocket L, Delaugerre C, Tamalet C, Schneider V, Izopet J, Masquelier B, Rouzioux C, Meyer L, Costagliola D; ANRS AC11 Resistance Group; Cohort PRIMO ANRS CO 6; FHDH ANRS CO4 Study Groups.
-->  Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France.
---->  AIDS 2009; 23(6):717-24.
      75  
Fontas E, Kousignian I, Pradier C, Duvivier C, Poizot-Martin I, Durier C, Jarrousse B, Weiss L, Levy Y, Costagliola D, on behalf of the FHDH ANRS CO4 and ANRS CO14.
-->  Interleukine 2 therapy does not increase the risk of Hodgkin’s or non Hodgkin’s lymphoma in HIV-infected patients; results from FHDH ANRS CO4.
---->  J Acquir Immune Defic Syndr 2009; 50(2): 206-214.
        76  
Grabar S, Selinger-Leneman H, Abgrall S, Pialoux G, Weiss L, Costagliola D.
-->  Prevalence and comparative characteristics of long-term non-progressors and HIV controller patients in the French Hospital Database on HIV.
---->  AIDS 2009 ; 23(9):1163–1169.
      77  
Guiguet M, Boué F, Cadranel J, Lang JM, Rosenthal E, Costagliola D, on behalf of the Clinical Epidemiology Group of the FHDH-ANRS CO4 cohort.
-->  Effect of immunodefi ciency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study.
---->  Lancet Oncology 2009; 10: 1152-1159.
        78  
Guiguet M, Kendjo E, Carcelain G, Abgrall S, Mary-Krause M, Tattevin P, Yazdanpanah Y, Costagliola D, Duval X, on behalf of the FHDH-ANRS CO4 Epidemiology Group.
-->  CD4 cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naïve patients with CD4 cell counts above 200/mm³.
---->  Antivir Ther 2009, 14(3): 451-457.
      79  
Hernan MA, McAdams M, McGrath N, Lanoy E, Costagliola D.
-->  Observation plans in longitudinal studies with time-varying treatments.
---->  Stat Methods Med Res 2009; 18(1): 27-52.
        80   
Lanoy E, Lewden C, Lièvre L, Tattevin P, Boileau J, Aouba A, Chêne G, Costagliola D, ANRS CO4 FHDH and Groupe d’Etude Mortalité 2000.
-->  How does loss to follow-up influence cohort findings on HIV infection? A joint analysis of the French Hospital Database on HIV, Mortalité 2000 Survey and death certificates.
---->  HIV Med 2009; 10(4): 236-245.
      81   
Lanoy E, May M, Mocroft A, Phillips A, Justice A, Chêne G, Furrer H, Sterling T, D'Arminio Monforte A, Force L, Gill J, Harris R, Hogg RS, Kitahata M, Rockstroh J, Saag M, Staszewski S, de Wolf F, Sterne JAC, Costagliola D.
-->  Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements.
---->  AIDS 2009; 23(16):2199-2208.
        82   
Marin B, Thiébaut R, Bucher HC, Rondeau V, Costagliola D, Dorrucci M, Hamouda O, Prins M, Walker AS, Porter K, Sabin C, Chêne G on behalf of the CASCADE Collaboration.
-->  Non-AIDS defining deaths and immunodeficiency in the era of combination antiretroviral therapy. CASCADE, 1996-2006.
---->  AIDS 2009; 23(13):1743-1753.
      83   
Mocroft A, Sterne J, Egger M, May M, Grabar S, Hansjakob Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d’Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M.
-->  Variable impact on mortality of AIDS defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.
---->  Clin Infect Dis 2009; 48(8): 1138-115.
        84  
Moore DM, Harris R, Lima V, Hogg B, May M, Yip B, Justice A, Mocroft A, Reiss P, Lampe F, Chêne G, Costagliola D, Elzi L, J. Mugavero MJ, D'Arminio Monforte A, Sabin C, Podzamczer D, Fätkenheuer G, Staszewski S, Gill J, Sterne JAC.
-->  Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression.
---->  J Acquir Immune Defic Syndr 2009; 52(3):357-363.
      85  
Mouala C, Guiguet M, Houzé S, Damond F, Pialoux G, Viget N, Costagliola D, Le Bras J, Matheron S, on behalf of the FHDH-ANRS CO4 Clinical Epidemiology Group.
-->  Impact of HIV infection on severity of imported malaria is restricted to patients with CD4 cell counts<350/mm3.
---->  AIDS 2009; 23(15): 1997-2004.
        86  
Potard V, Weiss L, Lamontagne F, Rouveix E, Beck-Wirth G, Drogoul-Vey MP, Faouzi Souala M, Costagliola D and the French hospital database on HIV, ANRS CO4.
-->  Trends in post-infection CD4 cell counts and plasma HIV-1 RNA levels in HIV-1-infected patients in France between 1997 and 2005.
---->  J Acquir Immune Defic Syndr 2009; 52(3):442-426.
      87  
Sterne JAC, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, Jönsson Funk M, Geskus R, Gill J, Dabis F, Miró JM, Justice A, Ledergerber B, Fätkenheuer G, Hogg R, D’Arminio Monforte A, Saag M, Smith C, Staszewski S, Egger M, Cole SR (When to start consortium).
-->  Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.
---->  Lancet 2009; 373(9672): 1352-1363.
        88  
Zwahlen M, Hogg R, May M, Costagliola D, Lewden C, Justice A, von Wyl V, Egger M.
-->  Mortality of HIV-infected patients starting potent antiretroviral therapy: Comparison with general population in eight countries.
---->  Int J Epidemiol 2009; 38(6): 1624-1633.
Adresse Mentions légales Extranet Administration